| Not Yet Recruiting | BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases. NCT07474961 | Anne Louise Tølbøll Sørensen | Phase 4 |
| Suspended | Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation NCT06348147 | UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Not Yet Recruiting | DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM NCT07377435 | David Avigan | Phase 1 |
| Not Yet Recruiting | A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma NCT07518186 | Janssen Research & Development, LLC | Phase 3 |
| Not Yet Recruiting | ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor St NCT04579523 | Fred Hutchinson Cancer Center | Phase 1 |
| Not Yet Recruiting | Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype NCT07341867 | Andrew Hantel, MD | Phase 1 |
| Recruiting | Pre-malignant States to Hematologic Malignancies in Firefighters NCT06870760 | Wake Forest University Health Sciences | — |
| Not Yet Recruiting | Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel NCT07200089 | Washington University School of Medicine | Phase 1 |
| Not Yet Recruiting | Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multip NCT07285239 | PrECOG, LLC. | Phase 3 |
| Not Yet Recruiting | FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma NCT07446777 | University of Miami | N/A |
| Not Yet Recruiting | Validating Fish Oil's Role in Alleviating Bortezomib-Induced Neuropathy: A Multi-Method Study Integrating Big NCT07403071 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | — |
| Not Yet Recruiting | Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing NCT07485647 | Eden Biltibo | Phase 2 |
| Not Yet Recruiting | Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event NCT07499128 | National Cancer Institute (NCI) | N/A |
| Suspended | Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma NCT06876142 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Not Yet Recruiting | ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligibl NCT07247097 | Massachusetts General Hospital | Phase 2 |
| Not Yet Recruiting | A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy NCT07249528 | Memorial Sloan Kettering Cancer Center | N/A |
| Not Yet Recruiting | A Phase I Study of SHR-3836 in Patients With Multiple Myeloma NCT07490613 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 1 |
| Not Yet Recruiting | A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma NCT07336472 | Fortvita Biologics (USA)Inc. | Phase 1 / Phase 2 |
| Recruiting | Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma NCT07200102 | Washington University School of Medicine | Phase 1 |
| Recruiting | A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Rel NCT07452198 | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Phase 3 |
| Not Yet Recruiting | Halt Aging in Survivors of Blood Cancers: the HALTAging-1 Study NCT07292272 | University of Nebraska | Phase 2 |
| Not Yet Recruiting | Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma NCT05976555 | Medical College of Wisconsin | Phase 1 |
| Not Yet Recruiting | MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myel NCT07409454 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Not Yet Recruiting | BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM) NCT07009899 | Medical College of Wisconsin | Phase 2 |
| Not Yet Recruiting | A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male Subjects NCT07400744 | Qilu Pharmaceutical Co., Ltd. | Phase 1 |
| Suspended | The Feasibility and Effects of Exercise on Patients Suffering From Multiple Myeloma NCT04300335 | Medical University of Vienna | N/A |
| Recruiting | CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma NCT07340853 | Thomas Martin, MD | Phase 1 |
| Recruiting | A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma NCT07454382 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Mov NCT07409246 | AbbVie | Phase 1 |
| Recruiting | A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multi NCT07284758 | C4 Therapeutics, Inc. | Phase 2 |
| Not Yet Recruiting | A Clinical Study Evaluating the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory NCT07376720 | Donghua Zhang | N/A |
| Recruiting | Study of BMS-986453 in Newly Diagnosed Multiple Myeloma NCT07333261 | Susan Bal | Phase 1 |
| Recruiting | A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma NCT07266441 | Janssen Research & Development, LLC | Phase 2 |
| Recruiting | A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Partici NCT07258511 | Janssen Research & Development, LLC | Phase 3 |
| Not Yet Recruiting | Telemedicine-mHealth Symptom Cluster Intervention for Advanced Cancer Patients: Finding Our Center Under Stres NCT07102212 | Ohio State University Comprehensive Cancer Center | N/A |
| Not Yet Recruiting | DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Y NCT07440290 | Cancer Research UK | Phase 2 / Phase 3 |
| Not Yet Recruiting | Isa-VRD in TIE HRMM NCT07334535 | Peking Union Medical College Hospital | Phase 4 |
| Recruiting | A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Me NCT07225738 | City of Hope Medical Center | — |
| Recruiting | JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma NCT07336823 | Shenzhen Genocury Biotech Co., Ltd. | EARLY_Phase 1 |
| Recruiting | A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myel NCT06980480 | Takeda | Phase 3 |
| Not Yet Recruiting | A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Pa NCT07227311 | GlaxoSmithKline | Phase 2 |
| Recruiting | A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Et NCT07095452 | AbbVie | Phase 2 / Phase 3 |
| Not Yet Recruiting | Effects of Controlled Breathing Added to Therapeutic Exercise in Multiple Myeloma NCT07312942 | Universidad Complutense de Madrid | N/A |
| Recruiting | An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers NCT07226934 | Washington University School of Medicine | N/A |
| Not Yet Recruiting | A Prospective, Multicenter, Diagnostic Study Evaluating 68Ga-BCMA PET/CT for Targeting BCMA Expression in Mult NCT07319897 | Peking University First Hospital | Phase 2 / Phase 3 |
| Recruiting | A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients Wi NCT06932562 | European Myeloma Network B.V. | Phase 3 |
| Recruiting | The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and NCT07285044 | Mayo Clinic | Phase 2 |
| Recruiting | A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma NCT07294625 | The First Affiliated Hospital with Nanjing Medical University | EARLY_Phase 1 |
| Recruiting | A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Pl NCT07179679 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | ICOPE Program Feasibility in the Management of Myeloma Patients NCT06247189 | University Hospital, Toulouse | N/A |
| Recruiting | Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redri NCT06910124 | Dickran Kazandjian, MD | Phase 2 |
| Recruiting | Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients NCT06514508 | Guangzhou Gloria Biosciences Co., Ltd. | Phase 3 |
| Not Yet Recruiting | A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancie NCT07255898 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMS NCT07448935 | Fondazione IRCCS Policlinico San Matteo di Pavia | — |
| Recruiting | Investigating the Pathogenic Role of N-glycosylation in AL Amyloidosis: Molecular Bases, Diagnosis, and Treatm NCT07448779 | Fondazione IRCCS Policlinico San Matteo di Pavia | — |
| Recruiting | A Dietary Study for People With Multiple Myeloma NCT07226609 | Memorial Sloan Kettering Cancer Center | N/A |
| Recruiting | Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma NCT07497165 | Shanxi Bethune Hospital | — |
| Recruiting | Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Contai NCT07413809 | The Affiliated People's Hospital of Ningbo University | Phase 3 |
| Recruiting | Mozobil for Autologous Hematopoietic Stem Cell Transplantation NCT07188090 | Thomas Jefferson University | Phase 2 |
| Recruiting | Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple NCT06517017 | University of Utah | Phase 2 |
| Recruiting | A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Me NCT06988488 | Celgene | Phase 1 / Phase 2 |
| Recruiting | A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel NCT07149857 | Janssen Research & Development, LLC | Phase 2 |
| Recruiting | Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction NCT07489534 | Daihong Liu | Phase 2 |
| Recruiting | Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic a NCT07101445 | Emory University | Phase 4 |
| Recruiting | ERd Combination Treatment in Newly Diagnosed Multiple Myeloma NCT06997081 | University of Miami | Phase 2 |
| Not Yet Recruiting | Risk-adapted Therapeutic Strategy in +1q NDMM NCT07045168 | FengYan Jin | — |
| Recruiting | Comparison of the Effects of Apixaban on Thrombin Generation in Patients With de Novo Multiple Myeloma NCT06474182 | Centre Hospitalier Universitaire de Saint Etienne | N/A |
| Recruiting | Hypofractionation (Radiation) Trial for Multiple Myeloma NCT06270888 | University of Chicago | Phase 1 |
| Not Yet Recruiting | Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma NCT06580223 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 3 |
| Not Yet Recruiting | UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma NCT06698744 | David Wald | Phase 1 |
| Not Yet Recruiting | A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participant NCT07090954 | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients NCT06572605 | City of Hope Medical Center | Phase 1 / Phase 2 |
| Recruiting | Observational Study on the Combination of Selinexor With Bortezomib and Dexamethasone for the Treatment of MM NCT06933277 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Recruiting | Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistam NCT06993675 | Noffar Bar | Phase 2 |
| Recruiting | A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma NCT07105059 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Recruiting | Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug ( NCT06896916 | AbbVie | Phase 1 |
| Not Yet Recruiting | Gustabor Phase 1 - AI-based Creation of a Nutritional Plan to Compensate for Chemotherapy-induced Taste Disord NCT07040189 | Wuerzburg University Hospital | N/A |
| Recruiting | A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenici NCT07073547 | AstraZeneca | Phase 1 |
| Recruiting | Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma NCT06348108 | Alfred Chung, MD | Phase 1 |
| Recruiting | A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma NCT07099391 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Recruiting | A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With NCT06953960 | AbbVie | Phase 1 / Phase 2 |
| Recruiting | Quantitative and Qualitative Monocytes Analysis and Their Impact on CART Cells Reponse in Multiple Myeloma NCT07180992 | Centre Hospitalier Universitaire, Amiens | — |
| Not Yet Recruiting | CAR-T vs. Auto-SCT: Which Works Better for New Myeloma Patients? NCT07070934 | Xuzhou Medical University | Phase 2 |
| Not Yet Recruiting | A Study of Anti-BCMA CAR-T Therapy in Newly Diagnosed Myeloma Patients Who Are Transplant-ineligible NCT07070960 | Xuzhou Medical University | N/A |
| Recruiting | In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies NCT07239323 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Not Yet Recruiting | A Study on the Use of Sulpegfilgrastim to Prevent the Incidence of Neutropenia With Infection in Newly Diagnos NCT07018271 | The First Affiliated Hospital of Soochow University | N/A |
| Recruiting | A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myel NCT06892522 | AbbVie | Phase 1 / Phase 2 |
| Not Yet Recruiting | Proteomic Analysis of Patients Undergoing Bariatric Surgery NCT06787807 | Universidade Federal de Pernambuco | N/A |
| Active Not Recruiting | Korean Post Marketing Surveillance for ELREXFIO (Elranatamab). NCT06581848 | Pfizer | — |
| Recruiting | Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma NCT06461988 | Stanford University | Phase 2 |
| Not Yet Recruiting | The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethaso NCT07015021 | The First Affiliated Hospital of Soochow University | N/A |
| Recruiting | A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma NCT07030517 | Johnson & Johnson Private Limited | Phase 4 |
| Recruiting | A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relap NCT06934044 | Hoffmann-La Roche | Phase 1 |
| Recruiting | Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia NCT06976476 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors NCT06976437 | YANRU WANG | EARLY_Phase 1 |
| Not Yet Recruiting | Multi-center Screening for Serum M Protein NCT06750965 | Zhujiang Hospital | — |
| Not Yet Recruiting | Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance NCT06931704 | Nantes University Hospital | Phase 2 |
| Recruiting | Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma NCT07032129 | Essen Biotech | Phase 1 / Phase 2 |
| Recruiting | Mosaic Trial for Stem Cell Transplant Recipients NCT06960993 | Northwestern University | N/A |
| Recruiting | PET/MR Scan With [68Ga]Ga-PentixaFor (CXCR4) vs Standard of Care (SOC) for Initial Staging and Follow up in Mu NCT06871176 | University Health Network, Toronto | N/A |
| Recruiting | Universal CAR-T Cell Therapy for MM NCT07248176 | Bioray Laboratories | N/A |
| Recruiting | Impact of an Early Warning System on the Prognosis of Patients With Hematological Malignancies Receiving Inten NCT06409767 | University Hospital, Angers | N/A |
| Recruiting | Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple My NCT06523699 | Washington University School of Medicine | Phase 1 |
| Not Yet Recruiting | Efficacy of Sequential BCMA CAR-T Cell Therapy Following Autologous Hematopoietic Stem Cell Transplantation in NCT06913192 | Xuzhou Medical University | Phase 1 |
| Not Yet Recruiting | Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia NCT06323447 | Leuko Labs, Inc. | — |
| Recruiting | Implementing a Randomized Control Trial to Test the Expanded Web-based Decision Aid NCT06910670 | Washington University School of Medicine | N/A |
| Not Yet Recruiting | CAR-T Cell Therapy Combined With Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory NCT06913179 | Xuzhou Medical University | Phase 1 |
| Recruiting | CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma NCT07249073 | Institute of Hematology & Blood Diseases Hospital, China | EARLY_Phase 1 |
| Recruiting | BCMA CAR-T for Dynamic High-risk Multiple Myeloma NCT06880393 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Recruiting | Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment NCT06784167 | OHSU Knight Cancer Institute | — |
| Recruiting | Real-World Mapping Antithrombotic Regimens in MM Patients on Treatment NCT06028087 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Recruiting | Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients NCT07169500 | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 / Phase 2 |
| Recruiting | CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study NCT06644625 | Wake Forest University Health Sciences | — |
| Active Not Recruiting | Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel NCT06523621 | Wake Forest University Health Sciences | Phase 2 |
| Recruiting | 64Cu-LLP2A for Imaging Hematologic Malignancies NCT06636175 | Washington University School of Medicine | EARLY_Phase 1 |
| Recruiting | Evaluation of a PREHABilitation Protocol Using Adapted Physical Activity (APA) for Multiple Myeloma Patients E NCT06789003 | Centre Hospitalier Henri Duffaut - Avignon | N/A |
| Recruiting | BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma NCT06793449 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Recruiting | A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elra NCT06799026 | David Avigan | Phase 1 |
| Recruiting | Self-administration of Subcutaneous Elranatamab in the Patients' Homes. NCT06015542 | Thomas Lund | Phase 2 |
| Withdrawn | Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells NCT07071909 | UNC Lineberger Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies NCT06758713 | The Third Affiliated Hospital of Southern Medical University | Phase 1 |
| Withdrawn | Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM NCT06352866 | Jack Khouri, MD | Phase 2 |
| Not Yet Recruiting | SIL as Maintenance Therapy in Multiple Myeloma NCT06744894 | Navy General Hospital, Beijing | Phase 2 |
| Not Yet Recruiting | To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma NCT06742138 | Qilu Pharmaceutical Co., Ltd. | Phase 3 |
| Recruiting | Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma NCT06759181 | Xuzhou Medical University | Phase 1 / Phase 2 |
| Not Yet Recruiting | Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic Transplant NCT05982275 | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | Phase 1 / Phase 2 |
| Recruiting | Characteristics and Clinical Significance of Gut Microbiota in Patients With Monoclonal Gammopathy NCT06690593 | Zhujiang Hospital | — |
| Not Yet Recruiting | Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple Myeloma NCT06705725 | Carbiogene Therapeutics Co. Ltd. | Phase 1 |
| Recruiting | Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance NCT06483100 | Washington University School of Medicine | Phase 2 |
| Recruiting | Elranatamab in Relapsed/Refractory Multiple Myeloma NCT06711705 | University of California, San Diego | Phase 2 |
| Recruiting | A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus D NCT06679101 | GlaxoSmithKline | Phase 3 |
| Recruiting | Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection NCT07028970 | Nanjing IASO Biotechnology Co., Ltd. | — |
| Recruiting | Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone NCT06561854 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Recruiting | A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma NCT06732232 | Shanghai Cell Therapy Group Co.,Ltd | EARLY_Phase 1 |
| Recruiting | Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients NCT05272826 | Canadian Myeloma Research Group | Phase 2 |
| Recruiting | Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykt NCT06623630 | Washington University School of Medicine | Phase 1 |
| Recruiting | A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Po NCT06768489 | Janssen Research & Development, LLC | Phase 1 |
| Recruiting | VitD3 Supplementation in Patients With Multiple Myeloma NCT05846880 | Amany Keruakous, MD, MS. | EARLY_Phase 1 |
| Recruiting | Study on the Clinical Efficacy of Teclistamab NCT06477783 | Universitaire Ziekenhuizen KU Leuven | — |
| Recruiting | Risk Stratification and MRD-driven Maintenance for MM After ASCT NCT06697483 | Peking University People's Hospital | N/A |
| Recruiting | A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma NCT06700395 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma o NCT06630104 | Mayo Clinic | N/A |
| Recruiting | Plan Development for Giving Teclistamab in the Outpatient Setting NCT06251076 | University Health Network, Toronto | Phase 4 |
| Recruiting | A Clinical Study to Evaluate the Safety and Efficacy of ESO-T01 in Treating Relapsed/Refractory Multiple Myelo NCT06691685 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | EARLY_Phase 1 |
| Recruiting | CAR T-cell Therapy in Patients With Renal Dysfunction NCT05909059 | Northside Hospital, Inc. | Phase 2 |
| Recruiting | Early Assessment of Cardiac Function After Treatment With CAR-T Cells NCT06350994 | Assistance Publique - Hôpitaux de Paris | — |
| Recruiting | A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell NCT06679829 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM NCT06518551 | Omar Nadeem, MD | Phase 1 / Phase 2 |
| Recruiting | Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure NCT06142396 | Augusta University | EARLY_Phase 1 |
| Completed | A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Follow NCT06547112 | Washington University School of Medicine | Phase 1 |
| Recruiting | A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) NCT06644118 | Zhejiang University | Phase 1 |
| Completed | The Burden of Multiple Myeloma on Patients and Caregivers Quality of Life: a Canadian Real-World Study NCT06610045 | PeriPharm | — |
| Completed | A Plant-Based Whole-Foods Meal Delivery Service for Patients With Multiple Myeloma Undergoing Autologous Hemat NCT06559709 | Fred Hutchinson Cancer Center | N/A |
| Not Yet Recruiting | Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells (ACT-001) in Patients With Relapsed or Refractorymultiple NCT06594211 | RenJi Hospital | N/A |
| Not Yet Recruiting | Bleeding in Multiple Myeloma NCT06482931 | University Medical Center Groningen | — |
| Recruiting | Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple My NCT06581640 | The First Affiliated Hospital of Xiamen University | Phase 2 |
| Recruiting | Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral NCT06398457 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | EARLY_Phase 1 |
| Recruiting | Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan NCT06588413 | Augusta University | Phase 3 |
| Active Not Recruiting | A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple NCT06550895 | Janssen Research & Development, LLC | Phase 2 |
| Recruiting | A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Mu NCT06698887 | Bristol-Myers Squibb | — |
| Recruiting | A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma NCT06999031 | The First Affiliated Hospital of Nanchang University | EARLY_Phase 1 |
| Active Not Recruiting | A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma NCT06381141 | Cullinan Therapeutics Inc. | Phase 1 |
| Completed | Biomarkers of AKI in Patients Receiving Daratumumab NCT06549634 | Brigham and Women's Hospital | — |
| Active Not Recruiting | Telehealth-based Symptom Management for Veterans Treated With Selinexor NCT06452446 | Durham VA Medical Center | — |
| Recruiting | Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma NCT06179888 | National Cancer Institute (NCI) | Phase 2 |
| Completed | A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory NCT06592222 | Pfizer | — |
| Recruiting | GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma NCT06566547 | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Phase 2 |
| Recruiting | A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events NCT06500884 | Janssen Research & Development, LLC | Phase 2 |
| Recruiting | A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refract NCT06413498 | Kite, A Gilead Company | Phase 3 |
| Recruiting | Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma NCT06185751 | Washington University School of Medicine | Phase 1 |
| Recruiting | IMMUNOPLANT for Newly Diagnosed Multiple Myeloma NCT06376526 | Dickran Kazandjian, MD | Phase 2 |
| Active Not Recruiting | A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Co NCT06577025 | Janssen Research & Development, LLC | Phase 2 |
| Recruiting | A Clinical Study of SHR-9539 in Patients With Multiple Myeloma NCT06484777 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 1 |
| Recruiting | Prehab Prior to Stem Cell Transplantation in Multiple Myeloma NCT06280924 | University of Alberta | N/A |
| Recruiting | Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients NCT06520176 | The Affiliated People's Hospital of Ningbo University | Phase 3 |
| Recruiting | ATRA and Carfilzomib in Plasma Cell Myeloma Patients NCT06536413 | The Methodist Hospital Research Institute | Phase 1 / Phase 2 |
| Recruiting | A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma NCT06083207 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 / Phase 2 |
| Active Not Recruiting | Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment ( NCT06169215 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma NCT06485076 | University Health Network, Toronto | N/A |
| Recruiting | Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With Hi NCT06207799 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Precision Medicine Study NCT06338150 | Icahn School of Medicine at Mount Sinai | — |
| Recruiting | Integrative Therapies in Multiple Myeloma NCT06515249 | Bnai Zion Medical Center | N/A |
| Recruiting | Remote Monitoring With Health-Coaching to Improve Quality of Life in Older Patients With Multiple Myeloma NCT06145581 | Mayo Clinic | N/A |
| Not Yet Recruiting | Clinical Outcomes and Prognostic Factors in Multiple Myeloma Patients NCT06457464 | Assiut University | — |
| Active Not Recruiting | Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, L NCT06353022 | Nantes University Hospital | Phase 2 |
| Recruiting | DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics NCT06296368 | UNC Lineberger Comprehensive Cancer Center | N/A |
| Recruiting | Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients NCT06505369 | North Estonia Medical Centre | Phase 2 |
| Active Not Recruiting | Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Par NCT06223516 | AbbVie | Phase 1 |
| Recruiting | Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection NCT06409702 | The First Affiliated Hospital of Soochow University | Phase 4 |
| Recruiting | Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma NCT06407947 | Shanghai Changzheng Hospital | EARLY_Phase 1 |
| Recruiting | Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy NCT06483139 | Brigham and Women's Hospital | — |
| Recruiting | Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma NCT05922501 | Massachusetts General Hospital | Phase 2 |
| Recruiting | Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adul NCT06158841 | AbbVie | Phase 3 |
| Recruiting | FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide- NCT06187441 | Stichting Hemato-Oncologie voor Volwassenen Nederland | Phase 3 |
| Recruiting | Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma NCT06429150 | Shenzhen Geno-Immune Medical Institute | Phase 1 / Phase 2 |
| Withdrawn | A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants Wi NCT06232707 | Celgene | Phase 3 |
| Recruiting | A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple Myeloma NCT06497738 | The First Affiliated Hospital with Nanjing Medical University | — |
| Unknown | Preliminary Assessment of [18F]BL40 in PET/CT Scans NCT06224309 | British Columbia Cancer Agency | — |
| Not Yet Recruiting | Examination of Trends in Multiple Myeloma Trial Patient Experiences NCT05860179 | Power Life Sciences Inc. | — |
| Recruiting | Telo Genomics Technology to Detect & Profile Multiple Myeloma MRD NCT05530096 | Sir Mortimer B. Davis - Jewish General Hospital | — |
| Recruiting | Intestinal Flora and Immunity in Monoclonal Gammopathy Patients NCT06539832 | Zhujiang Hospital | — |
| Not Yet Recruiting | A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of NCT05545202 | Pharmacosmos A/S | Phase 4 |
| Recruiting | Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R/RMM NCT06503107 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 1 / Phase 2 |
| Not Yet Recruiting | An Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple Myeloma NCT06379451 | Changzhou No.2 People's Hospital | EARLY_Phase 1 |
| Recruiting | Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma NCT06149910 | All4Cure | — |
| Not Yet Recruiting | Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL NCT06333509 | CARsgen Therapeutics Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Di NCT06182774 | Canadian Cancer Trials Group | Phase 3 |
| Recruiting | Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma NCT06048250 | City of Hope Medical Center | Phase 1 |
| Recruiting | Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma NCT06216158 | University of Heidelberg Medical Center | Phase 3 |
| Completed | PatIent exPeRiences and prEFerence of trEatment foR Multiple Myeloma NCT06322927 | The Christie NHS Foundation Trust | — |
| Recruiting | A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study NCT06271252 | OriCell Therapeutics Co., Ltd. | Phase 1 |
| Recruiting | PET Imaging Study of 68Ga-NB381 in Multiple Myeloma NCT06385652 | Peking University First Hospital | EARLY_Phase 1 |
| Not Yet Recruiting | Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease NCT06314698 | RenJi Hospital | Phase 3 |
| Not Yet Recruiting | Study of SYS6020 in BCMA-positive Multiple Myeloma NCT06359509 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | EARLY_Phase 1 |
| Recruiting | The Prognostic Value of CPCs Quantified by Flow Cytometry in Patients With Multiple Myeloma: a Prospective, Mu NCT06228794 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | — |
| Not Yet Recruiting | Registry of Haploidentical Hematopoietic Stem Cell Transplantation in Adult With Hematologic Disease NCT06286228 | Siriraj Hospital | — |
| Recruiting | A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03) NCT06464991 | Nanjing IASO Biotechnology Co., Ltd. | Phase 3 |
| Unknown | Comparison of the Complications in Multiple Myeloma Patients Who Received Autologous Stem Cell Transplantation NCT06286241 | Siriraj Hospital | — |
| Recruiting | 18F-Fluciclovine PET/CT in Multiple Myeloma NCT06103838 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With NCT06297226 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Phase 2 |
| Not Yet Recruiting | RAT-HEMATO : Return to Work After Malignant Hemopathy NCT06262789 | University Hospital, Angers | N/A |
| Recruiting | Elranatamab in R/R Multiple Myeloma NCT06138275 | Massachusetts General Hospital | Phase 2 |
| Recruiting | MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone NCT06042725 | Mayo Clinic | Phase 1 |
| Recruiting | Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen R NCT05887167 | Joshua Sasine, MD, PhD | Phase 1 |
| Unknown | Efficacy and Safety Evaluation of PD1-BCMA-CART NCT05308875 | Bioray Laboratories | N/A |
| Withdrawn | Marizomib Central Nervous System (CNS) NCT05050305 | Dana-Farber Cancer Institute | Phase 2 |
| Active Not Recruiting | Integrated Actionable Aging Assessment for Cancer Patients Pilot NCT05871008 | University of Colorado, Denver | N/A |
| Unknown | LI-TASTE Study: Light for Taste NCT06258096 | Academic Centre for Dentistry in Amsterdam | N/A |
| Unknown | A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma NCT06126237 | Keymed Biosciences Co.Ltd | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory NCT06163898 | Celgene | Phase 1 |
| Recruiting | A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in N NCT06121843 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Phase 1 |
| Recruiting | A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients NCT06215118 | Pfizer | Phase 1 |
| Recruiting | MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (M NCT06152575 | Pfizer | Phase 3 |
| Recruiting | Fall Risk Assessment and an Exercise Intervention for Prevention of Falls in Multiple Myeloma Patients NCT07044427 | University Hospital Heidelberg | N/A |
| Recruiting | Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients NCT06105554 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | COVID19 OutcomeS in Myeloma and the Impact of VaCcines NCT05831787 | ASH Research Collaborative | — |
| Recruiting | A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, a NCT06208150 | Janssen Research & Development, LLC | Phase 3 |
| Recruiting | PASCA-MM Study. Impact of the PASCA (PArcours de Santé au Cours du CAncer) Program on Complications Associated NCT05947136 | Centre Leon Berard | N/A |
| Unknown | A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma NCT06223646 | Novatim Immune Therapeutics (Zhejiang) Co., Ltd. | Phase 1 / Phase 2 |
| Withdrawn | Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant NCT05820763 | Washington University School of Medicine | Phase 2 |
| Unknown | A Clinical Study on the Whole-course Management (BCD-KPD-AutoHSCT) Scheme for Patients With RIMM NCT06203145 | Peking University First Hospital | N/A |
| Recruiting | A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma NCT06235229 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R NCT06196255 | Xuzhou Medical University | Phase 1 / Phase 2 |
| Recruiting | A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refr NCT06296121 | Biocad | Phase 3 |
| Recruiting | Iberdomide and Daratumumab As Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myelom NCT06107738 | Barbara Ann Karmanos Cancer Institute | Phase 2 |
| Recruiting | Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma NCT05572229 | University Hospital, Lille | Phase 2 |
| Recruiting | A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in A NCT05828511 | Regeneron Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Doxil/Caelyx BE Study NCT05567601 | Baxter Healthcare Corporation | Phase 1 |
| Recruiting | Sequential Therapy in Multiple Myeloma Guided by MRD Assessments NCT05231629 | University of Alabama at Birmingham | Phase 2 |
| Active Not Recruiting | Isa-Pom-Dex in Elderly/Frail Subjects With RRMM NCT05911321 | UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Recruiting | AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multi NCT06106945 | AstraZeneca | Phase 1 / Phase 2 |
| Recruiting | Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase NCT06100237 | Carl Ola Landgren, MD, PhD | Phase 2 |
| Recruiting | Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not NCT06463717 | First Affiliated Hospital of Zhejiang University | — |
| Active Not Recruiting | Psychosocial Mobile Application (THRIVE-M) for Patients With Multiple Myeloma NCT06073353 | Massachusetts General Hospital | N/A |
| Recruiting | DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma NCT06158269 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Recruiting | Study of ODX (OsteoDex) in Multiple Myeloma NCT06616389 | DexTech Medical AB | Phase 1 / Phase 2 |
| Recruiting | Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With NCT06189833 | Stichting European Myeloma Network | Phase 2 |
| Recruiting | Cardiac Toxicity and Prognostic Value of New Echocardiographic Indicators in the Treatment of Primary Multiple NCT06039735 | Qilu Hospital of Shandong University | — |
| Completed | Multiple Myeloma Yoga Pilot Study NCT06061302 | University of Arizona | N/A |
| Recruiting | A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma NCT05583617 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Recruiting | Mitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple NCT06246162 | Affiliated Hospital of Nantong University | Phase 1 / Phase 2 |
| Recruiting | Safety and Efficacy of APRIL-BAFF-Bicephali CAR-T in Relapsed, Refractory Multiple Myeloma NCT06132711 | Xuzhou Medical University | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study to Identify Barriers to Cellular Therapies for People With Plasma Cell Disorders NCT06126341 | Memorial Sloan Kettering Cancer Center | — |
| Unknown | Lapelga vs Gastrofil NCT06116734 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Phase 3 |
| Active Not Recruiting | Chaplain-Delivered Compassion Meditation to Improve Spiritual Care of Patients Receiving Stem Cell Transplanta NCT06328699 | Emory University | N/A |
| Recruiting | Whole Body MRI in Oncology NCT06895291 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | — |
| Recruiting | IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Can NCT06119685 | Indapta Therapeutics, INC. | Phase 1 / Phase 2 |
| Recruiting | Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma NCT05972135 | SCRI Development Innovations, LLC | Phase 2 |
| Active Not Recruiting | Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Tr NCT05889221 | Poitiers University Hospital | N/A |
| Recruiting | Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Mainten NCT06140966 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 |
| Recruiting | Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency NCT05879757 | Takeda | — |
| Active Not Recruiting | A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Ver NCT06045806 | Celgene | Phase 3 |
| Recruiting | A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gam NCT06083922 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Active Not Recruiting | A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleuce NCT05257083 | Stichting European Myeloma Network | Phase 3 |
| Recruiting | Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufacture NCT06357754 | Bristol-Myers Squibb | — |
| Recruiting | Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM) NCT06057402 | Pfizer | Phase 4 |
| Recruiting | Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM) NCT06087653 | Starton Therapeutics, Inc | Phase 1 / Phase 2 |
| Completed | Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory Drugs NCT06160167 | Bristol-Myers Squibb | — |
| Recruiting | A Cross-sectional Study on the Positive Rate of M Protein Based on a Highly Sensitive Serum M Protein Detectio NCT06082284 | Zhujiang Hospital | — |
| Recruiting | Analysis of the Resistance and Sensitivity Mechanisms to Teclistamab by Focusing on Single Immune Cell Examina NCT05945524 | University Hospital, Toulouse | N/A |
| Recruiting | A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy NCT06066346 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | A Comparative Clinical Study to Determine the Optimal Initial Therapy for Multiple Myeloma NCT06151717 | Mayo Clinic | — |
| Recruiting | A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Mono NCT06055894 | Memorial Sloan Kettering Cancer Center | N/A |
| Active Not Recruiting | Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients NCT06062537 | Intergroupe Francophone du Myelome | — |
| Completed | Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple NCT05986682 | Duke University | — |
| Recruiting | PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma NCT05956457 | Pack Health | N/A |
| Unknown | CURATE.AI Optimized Modulation for Multiple Myeloma NCT03759093 | National University Hospital, Singapore | Phase 2 / Phase 3 |
| Terminated | Providing Cancer Care Closer to Home for Patients With Multiple Myeloma NCT05971056 | Washington University School of Medicine | N/A |
| Completed | A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Mul NCT06504524 | Pfizer | — |
| Recruiting | High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT) NCT07205523 | Yigeng Cao,MD,PhD | — |
| Withdrawn | Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell NCT05013437 | Koen van Besien | EARLY_Phase 1 |
| Unknown | Cyclin D1 as a Prognostic Factor in Multiple Myeloma and Its Association With the Immunological Prognostic Fac NCT05995808 | Sohag University | N/A |
| Terminated | Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma NCT05908396 | IGM Biosciences, Inc. | Phase 1 |
| Recruiting | Discontinuation Study NCT05866757 | University College Cork | N/A |
| Recruiting | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer NCT05969860 | Mayo Clinic | Phase 2 |
| Unknown | the Safety and Efficacy of SENL103 Autologous T Cell Injection NCT06067581 | Hebei Senlang Biotechnology Inc., Ltd. | EARLY_Phase 1 |
| Recruiting | DAratumumab and REvlimid REfractory MM NCT06541860 | Fondazione IRCCS Policlinico San Matteo di Pavia | — |
| Recruiting | Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients NCT05776979 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Scalp Cooling to Prevent Hair Loss in Patients Undergoing Stem Cell Transplantation for Multiple Myeloma NCT05961215 | Cedars-Sinai Medical Center | N/A |
| Active Not Recruiting | Biomarker for Infection Risk in CLL and MM NCT05844033 | Massachusetts General Hospital | — |